Superficial Bladder Cancer: Intravesical Chemotherapy and Tumour Progression to Muscle Invasion or Metastases
- 1 December 1986
- journal article
- research article
- Published by Wiley in British Journal of Urology
- Vol. 58 (6) , 659-663
- https://doi.org/10.1111/j.1464-410x.1986.tb05907.x
Abstract
Summary— Of 299 patients who presented with superficial bladder cancer (Ta, TI), 60 were treated by intravesical chemotherapy (Epodyl, methotrexate or mitomycin C). The rate of tumour progression to muscle invasion or metastases was identical for each intravesical regime. There was no evidence that mitomycin C promoted tumour progression. Carcinoma in situ in non‐tumour‐bearing urothelium was the most significant predictive factor for progression to muscle invasion or metastases.This publication has 14 references indexed in Scilit:
- Mitomycin C in Superficial Bladder Cancer: 24‐month Follow‐upBritish Journal of Urology, 1985
- The Effect of Intravesical Thiotepa on the Recurrence Rate of Newly Diagnosed Superficial Bladder Cancer. An MRC StudyBritish Journal of Urology, 1985
- DNA/RNA Ratio in Bladder Cancer: a Factor Indicating the Recurrence Rate?British Journal of Urology, 1985
- Intravesical Mitomycin C Therapy for Superficial Bladder Cancer. Report of a Multicentre Phase II StudyBritish Journal of Urology, 1985
- Intravesical Methotrexate in the Treatment of Superficial Bladder CancerBritish Journal of Urology, 1984
- Prognostic Significance of Biopsy Results of Normal‐looking Mucosa in Cases of Superficial Bladder CancerBritish Journal of Urology, 1983
- A Phase II Study of lntravesical Mitomycin C in the Treatment of Superficial Bladder CancerBritish Journal of Urology, 1983
- Flat Carcinoma in situ of BladderBritish Journal of Urology, 1975
- A computer program for comparing K samples with right-censored dataComputer Programs in Biomedicine, 1972